A phase II trial of chemotherapeutic agents in patients with diffuse large B-Cell lymphoma
The purpose of this study is to find out what effects, good and/or bad, the addition of lenalidomide to standard chemotherapy (RCHOP).
Contact: Katie Colbeck, 413-794-9875
Cancer - Lymphoma,
- D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
- Baystate Franklin Medical Center, 164 High Street, Greenfield, MA
Newly diagnosed diffuse large B-cell lymphoma expressing CD20 antigen
Interventional (Clinical Trial)